{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T03:15:14Z","timestamp":1648782914420},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BTT"],"DOI":"10.2147\/btt.s60523","type":"journal-article","created":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T16:58:02Z","timestamp":1453741082000},"page":"9","source":"Crossref","is-referenced-by-count":0,"title":["Emerging treatments in Castleman disease – a critical appraisal of siltuximab"],"prefix":"10.2147","author":[{"given":"Sagar","family":"Lonial","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Koff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,1]]},"container-title":["Biologics: Targets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=28760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T18:29:45Z","timestamp":1477852185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/emerging-treatments-in-castleman-disease-ndash-a-critical-appraisal-of-peer-reviewed-article-BTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/btt.s60523","relation":{},"ISSN":["1177-5491"],"issn-type":[{"value":"1177-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}